{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'specific eCRF completion guidelines. For the purposes of this study, pre-screening', 'failures, screening failures, run-in failures and randomisation failures will be defined as', 'follows:', 'Pre-screening failures: those participants that sign the informed consent document but', 'do not have a Visit 1 (Screening) procedure.', 'Screening failures: those participants that complete at least Visit 1 (Screening)', 'procedure but do not enter the run-in period. A participant who completes Visit 1', 'assessments and is dispensed the study medication for the run-in period is considered to', 'have entered the run-in period.', 'Run-in failures: those participants that enter the run-in period but do not have any Visit', '2 (Randomisation) procedures, or those participants that complete at least one Visit 2', '(Randomisation) procedure but do not enter the double-blind study treatment period. Any', 'participant who completed the run-in period and meets the randomisation criteria and is', 'dispensed the double-blind study treatment at Visit 2 is considered to have entered the', 'treatment period.', '7.', 'TREATMENTS', 'Study treatment is defined as any investigational treatment(s), marketed product(s),', 'placebo, or medical device(s) intended to be administered to a study participants', 'according to the study protocol.', '7.1.', 'Treatment Groups and Duration', 'Participants who meet all the eligibility criteria and who have successfully completed all', 'protocol procedures at Screening will enter the 4-week run-in period and will take open-', 'label tiotropium 18 mcg via the HandiHaler once daily plus placebo via the ELLIPTA.', 'Following the run-in period, participants who meet randomisation criteria will be', 'randomised (1:1) to one of the following double-blind, double-dummy treatment groups', 'for 84 days:', 'Either:', 'FF/UMEC/VI 100/62.5/25 mcg via the ELLIPTA once daily in the morning', '+ placebo to match tiotropium via HandiHaler once daily in the morning', 'or,', 'Tiotropium 18 mcg via HandiHaler once daily in the morning', '+ placebo via the ELLIPTA once daily in the morning', 'The ELLIPTA contains 30 doses (FF/UMEC/VI or placebo) and participants will be', 'instructed to administer one dose from their ELLIPTA once daily in the morning.', '48']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'Tiotropium or matching placebo: Contents of 1 capsule (18 mcg) inhaled once daily', 'using HandiHaler device. Note: To ensure drug delivery, two inhalations of the contents', 'of each capsule should be performed.', 'Descriptions of the study treatments administered via the ELLIPTA and the Handihaler', 'are provided in Table 2 and Table 3 respectively.', '49']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'Table 2', 'Description of FF/UMEC/VI Inhalation Powder in ELLIPTATM', 'First strip', 'Second strip', 'FF/UMEC/VI', 'GW642444 and GSK573719', 'GW685698 blended with', 'blended with lactose and', 'lactose', 'magnesium stearate', 'Dosage Form', 'ELLIPTA with 30 doses (2 strips with 30 blisters per strip)', 'Unit Dose', '25 mcg per blister GW642444, 62.5', '100 mcg per blister', 'Strengths', 'mcg per blister GSK573719', 'Physical', 'Dry white powder', 'Dry white powder', 'description', 'Route of', 'Administration', 'Inhaled', 'First strip', 'Second strip', 'Placebo to match', 'Lactose', 'Lactose/Magnesium Stearate', 'Dosage Form', 'ELLIPTA with 30 doses (2 strips with 30 blisters per strip)', 'Unit Dose', 'NA', 'Dry white powder', 'Strengths', 'Physical', 'Dry white powder', 'NA', 'description', 'Route of', 'Inhaled', 'Administration', 'Table 3', 'Description of Tiotropium bromide in HandiHaler', 'Tiotropium 18 mcg', 'HandiHaler', 'Dosage form', 'Capsule', 'Unit dose strength', '18 mcg', 'Physical description', 'Hard gelatin capsule containing 18mcg', 'tiotropium bromide blended with lactose', 'Route of administration', 'Inhaled', 'Placebo to match Tiotropium', 'HandiHaler', 'Dosage form', 'Capsule', 'Unit dose strength', 'NA', 'Physical description', 'Hard gelatin capsule containing lactose', 'Route of administration', 'Inhaled', '50']\n\n###\n\n", "completion": "END"}